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Abstract
Technology has the ability to change the way clinical trials are conducted. Technology utilization
has expanded into research in the form of handheld smartphones, wearables, and social media.
This project explored technologies and assessed which of those technologies are being utilized at
a community hospital. A survey was designed, developed, and disseminated to principal
investigators and co-investigators of research within the hospital. The results showed that few of
the technologies included in the assessment are being utilized by the researchers at the hospital.
The most popular technology category being utilized by the researchers is smartphone
technology. This research could contribute to the knowledge about the utilization of research
technologies to society, as well as to the operational directors of research within the community
hospital, which could help reveal which technologies are most useful. This research could also
aid in the assessment of technology utilization over time within the same hospital.
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Chapter 1: Introduction

Technology is being incorporated into the design of clinical trials, and may be able to
change the future of clinical research (Rosa, Campbell, Miele, Brunner, & Winstanley, 2015).
There are different fonns of clinical research, and clinical trials can be conducted differently.
Clinical trials may be investigator sponsored, academic sponsored, or pharmaceutical industry
sponsored. Trials may be conducted at a physician's office, a hospital, a university clinical
research center, or a dedicated clinical research site. Research can include data collection, such
as retrospective or observational studies, or interventions, such as medically inserted devices,
patient-wearable devices, or pharmaceutical drugs. Additionally, research may include sponsor
funded (clinical trials), retrospective data collection, and investigator-initiated research.
Traditionally, clinical trials were executed using conventional methods, such as face-to
face recruitment and enrollment, administration of interventions, and data collection (Rosa et al.,
2015). Newspapers and radio advertisements were used for participant recruitment. Follow-up
assessments were conducted via mail or telephone, and data were collected using paper and
pencil methods. Storage of the collected data took physical space. In the late l 980's and early
l 990's, personal digital assistants (PDAs) were adopted into some clinical trials (Coons et al.,
2014). These devices allowed temporary data storage on the device until the data could be
uploaded to a central server. Electronic data capture (EDC) systems are now being used in the
majority of clinical trials and significantly decrease the amount of paper needing to be stored.
These EDCs can be monitored remotely, which allows sponsor companies and investigators to
ensure data integrity without the additional expense of travel to each clinical trial site.
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Advancements in electronic participant reported outcomes (ePRO) data collection have
improved the accuracy and integrity of clinical trial data, which is why regulators encourage its
use (Coons et al., 2014). Electronic capture of clinical trial source data is usually preferred over
paper-based data collection. Improved protocol compliance, avoidance of secondary data errors,
less administrative burden, and more accurate and complete data can be seen with the use of
ePRO systems.
Another technology improvement in participant-reported outcomes is an emerging trend
coined the 'Bring Your Own Device' (BYOD) approach. Participants use their own smartphone
or internet-enabled device to complete field-based participant reported outcome (PRO)
assessments. These devices can include smartphones, laptop and desktop computers, tablets, or
internet-enabled televisions. Gwaltney et al. (2015) explored this trend in the use of personal
devices for ePRO assessments and how they are implemented in clinical trials. The authors
found that this departure from traditional methods can reduce costs, reduce training time, reduce
study site burden, and keep study start-up times to a minimum.
Smartphone applications and use of smartphones in clinical trials can make support,
information, and monitoring available almost constantly. One randomized clinical trial of a
smartphone, called the Addiction-Comprehensive Health Enhancement Support System (A
CHESS), showed that the use of a smartphone application designed to improve continuing care
for alcohol use disorders may have significant benefit to participants (Gustafson et al., 2014).
Multi-featured smartphones offered emotional and instrumental support any place and any time
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study participants needed it. More recently, companies such as Apple and Google have expanded
their teclrnology into the research realm. On March 9, 2015, Apple (n.d.) presented its
ResearchKit™, which is software designed for medical and health research. This software allows
researchers to create apps for research utilization, and it works flawlessly with Apple's (n.d.)
CareKit™, which is an open source framework that assists users in managing their health and
connecting them to healthcare teams.
A very popular trend in research technology is using wearable data collection devices,
such as a watch or bracelet. Google maintains a health company, Verily Life Science LLC,
which in 2017 unveiled a watch that unobtrusively but continuously collects physiological data
from participants (Regalado, 2017). This device can capture heart rate, movement data, electrical
conductance of the skin, and electrocardiograms. This watch was developed as an investigational
device to be used in clinical trials. Clinical wearable devices allow clinical trial participants ease
of use and clinical site coordinators and principal investigators easy access to data. Wearable
devices enable the collection of unobtrusive, frequent, and continuous data, which, as shown by
Czaja, Gold, Bain, Hendrix, and Carrillo (2017), may be able to capture subtle changes in
cognition and functional capacity as well. Wearable technologies in healthcare may also be able
to offer personalized and remote care to pregnant participants for fetal monitoring, elderly
participants for fall detection and prevention, and cuff-less and continuous monitoring of blood
pressure. Wearable devices in healthcare are becoming increasingly popular for these reasons.
The global healthcare wearable device market could reach revenues of 18.9 billion dollars by
2020 (Fassbender, 2016).
Just as the wearable healthcare technology market is expanding, enthusiasm for social
networks as an avenue to reach more potential study participants has also been explored within
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research settings. Social media can be used as an avenue to promote awareness of research
activities and the results of research studies, and may also help industry sponsors by
commercializing the results, which in tum bring bigger benefits and profits more quickly (Jaring
& Back, 2017). Use of hashtags on social media can also be an avenue of tracking how many
people are interested in the topic (Devitt, 2016). Some researchers are even considering
recruiting study participants through social media and other online avenues. Gupta et al. (2015)
found that the use of the internet provides a way to make communication interactive. Participants
can be tracked at a granular level, and the use of online media for recruitment is more cost
effective, interactive, personalizable, and tractable when compared to offline media recruitment
efforts. Social media sites offer a new way to recruit young participants into research.
Technological changes and the addition of social media utilization in research have the most
implications for young people, as they are underrepresented in medical and population-based
studies in the United States, and the addition of recruitment through social media could help to
improve enrollment of these younger generations, thus improving representation of those
generations in medical studies (Fenner et al., 201 2).
Existing and emerging technologies can be extremely advantageous for clinical trials if
they are recognized and utilized properly. Science and technology move very quickly, and the
culture of communication has considerably changed in recent years, to a culture where potential
research participants are surrounded daily with personal technology through devices and
internet-based knowledge such as smartphones and social media. Internet-based communication
and mobile technologies have become the norm for society and participants. As reported by Rosa
et al. (2015), the world quickly went from interactive video games on a Wii™ system, to Siri™,
a voice activated personal assistant, in the amount of time that it takes to design, implement, and
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publish findings from a clinical trial. Technology can provide ease of use as well as higher
quality data collection capabilities. The time has come when we must think about how we can
make clinical trials more convenient for participants, and ensure they are active and engaged
participants.
With all of the emerging and new technologies available for clinical trial use, it is
pertinent that principal investigators are aware of these technologies. Principal investigators hold
the responsibility for the proper conduct of research at a study site. Utilizing recent technologies
may offer a way to lessen the workload and time spent on tedious tasks involved with the trial.
Use of recent technologies may also engage both the principal investigator and the participant.
Physicians' level of engagement can have significant effect on the overall success of a study and
its components, such as participant recruitment and retention, follow-up, and quality of data
collection (Zalay, Springer, Arts, & Eisenhauer 2018). New technologies can make clinical trials
more appealing to participants because of the convenience. Mobile phone apps, wearables, and
use of social media are just three new technologies that can help to reduce cost, improve
enrollment, and collect new forms of data for some clinical trials.
Purpose of the Study
The purpose of this study was to examine and measure the utilization of research
technologies by clinical research principal investigators and co-investigators who have
conducted research within the prior 24 months at a community hospital.

UTILIZATION OF RESEARCH TECHNOLOGIES

6

Research Question
Are clinical research investigators at a community hospital utilizing recent advancements
in technology that can be applied to clinical research?
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Chapter 2: Methods
The study was submitted for review to the community hospital institutional review board
(IRB) on January 3, 2019. The study received exemption status from the community hospital
IRB on January 1 8, 2019. Following the list of abbreviations (Appendix A), is the hospital IRB
approval letter (Appendix B). The study was then submitted for review to Eastern Michigan
University (EMU) University Human Subjects Review Committee (UHSRC) on January 2 1 ,
2019, and received exemption status on January 23, 2019 (Appendix B). The survey tool can be
found in Appendix C, followed by the researchers training documents in Appendix D.
Eligibility
The population that was identified and used for this study included adult (18 years or
older) clinical research principal investigators and co-investigators listed on a delegation of
authority log within the last 24 months and who work under the direction of one of the three
research departments within the community hospital. Excluded from this project were any
research projects that were found to be in conflict with this project (deemed applicable by the
operational directors of research) and any investigator who lacked comprehension of the English
language due to the survey assessment only being available in English.
Sources of Participants
The administrative assistant to the IRB was contacted at the community hospital prior to
the launch of the research project in order to request assistance of the research project. The
administrative assistant retains a list of principal investigators and co-investigators actively
responsible for research conducted at the hospital. The administrative assistant was asked to
forward study emails to the clinical research principal investigators with an embedded survey
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link in order to maintain participant confidentiality. Subsequent contact with the principal
investigators was through the administrative assistant and not the researcher. Emails were drafted
and reviewed by the community hospital IRB. The first email introduced participants to the
research topic, explained the intentions of the survey, and explained consent by participation.
The email also contained the link to the survey assessment. Follow-up emails included a thank
you for participation, as well as a reminder to those who had not completed the survey yet that
there was still time to complete it, and the link to the survey.
Design
The survey was designed and developed as a mixture of open and structured (fixed
response) assessments (Appendix C). The opening page of the survey was the consent form.
Participants who agreed to consent were then directed to the survey. Persons who chose to deny
consent were thanked for their time and were not shown the survey. At the top of the survey,
clear intentions informed participants of why the data were being collected and what the data
were to be used for. Clear instructions on how to fill out the survey properly were also included.
The survey consisted of brief questions and was estimated to take investigators less than five
minutes to complete. The questionnaire used was not validated, but the survey was tested on nine
people as a pilot to ensure all questions could be answered, which allowed the researcher time to
make any necessary changes. The researcher made changes after the pilot phase to ensure good
survey flow and participant understanding of categories and questions. The researcher included a
statement to allow participants to skip any questions that made them uncomfortable as requested
by the community hospital IRB and a full consent (by participation) as requested by the EMU
UHSRC. The survey was voluntary.
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The survey consisted of 10 questions and three major categories that were collapsed for
ease of use. The participants were asked about three categories that included wearable data
collection technology, smartphone data collection technology, and social media technology
utilization in research. Each of these categories included multiple choice answers that supplied a
specific type of technology that fit into that category.
The first four questions collected information pertaining to what role the participant had
in clinical research, how long they had been engaged in research, and what type of research they
were engaged in. The three categories focused on the technology that the participants had used in
their current research studies. These categories were patient-wearable data collection technology,
smartphone technology, and social media. Two questions assessed whether the participants felt
well informed about recent technological advancements that can be utilized in research and
whether they believe these advancements are helpful to research within the healthcare industry.
A final open-ended question asked participants to list any other technologies they utilize in their
current research that were not mentioned in the survey.
Risks and Benefits
This was a minimal-risk study. No specific procedures, situations, or materials posed
serious hazards to participants or personnel. The study was deemed minimal risk because, as
with all survey research, there is always a small risk of breach of confidentiality pertaining to the
survey responses. Data security measures minimized these risks, and there was no risk of
disclosure of protected health information (PHI). Subject safety was ensured because no
demographic information was collected with the surveys, and the surveys were returned in a
fashion that did not correlate responses to any personally-linked email. In addition, the
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researcher did not have access to any individual email addresses, and the administrative assistant
to the IRB forwarded the emails with the survey link to the principal investigators and co
investigators. The online survey used a public URL in order to keep all IP addresses
confidential. The survey link was a single, reusable, anonymous link that was unable to track
identifying information of respondents. Minimal discomfort at answering the survey questions
was considered another minimal risk, although unlikely. Participants were able to skip questions
that may have made them uncomfortable.
There was no direct benefit to the principal investigators who participated in the survey.
Benefits to society included understanding utilization of research technology within a
community hospital. The operational directors of research within the community hospital could
also find this knowledge beneficial.
Data Analysis
The researcher, under the direction of Jim Pellerin, a statistics assistant for the EMU
Graduate School, conducted all data analysis. Qualtrics® survey tool resources for data analysis
were utilized. No protected health information (PHI) was collected or included in any data
analysis. Missing data were not adjusted for in statistical analysis. Data were collected from the
online survey tool and populated into a Microsoft Excel spreadsheet labeled with the individual
variables for analysis. Non-parametric testing was conducted. Spearman's rho was used to
measure the strength of association between variables. SPSS™ was used for analysis.
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Chapter 3: Results

The survey was disseminated to 1 05 Pis and CO-Is (researchers) at a community hospital.
The survey was launched on January 25, 20 1 9, and was available for participation until February
1 5 , 201 9. The survey contained 1 0 questions, and did not collect any demographic information to
ensure participant confidentiality and anonymity. Of those 1 05 contacted, 29 (27.6%) Pis and
Co-Is consented to participate in the survey, one respondent declined consent, and 75 recipients
(7 1 .4%) did not respond. Analysis conducted in this study included detailed analysis of the
responses from 29 respondents.
Participants were asked to only complete the entire survey if they had been engaged in
research within the prior 24 months. Participants who had not been engaged in research for the
previous 24 months were asked to only complete the questions that asked them to assess how
useful they feel research technology is to the healthcare industry and the question that asked how
well informed they feel of research technologies(Questions 8 and 9 on survey; Appendix C). The
number of responses to each question varied due to the design of the survey. Questions 3 through
7 included the option to select "all that apply," so we expected to see the number of responses
vary from question to question. None of the 1 0 questions returned 29 responses. Figure 1 shows
the dissemination and response to the survey, while Table 1 shows the number of responses to
each survey question.
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Survey Disemination and Responses

■ Diseminated surveys

Answered su rveys

Figure 1. Survey dissemination and response.

Table 1
Survey Response Numbers to Individual Questions
Question
Number**

QI

Q2

Q3**

Q4 **

Q5**

Q6**

Q7**

Q8

Q9

QI0

N*

25

22

28

23

22

23

21

25

25

4

* N of responses = 29
** Respondents allowed to select "all that apply"

The participants were asked if they had been engaged in research in the previous 24
months as a P.l., Co-I, or "not been engaged." Of the 29 respondents, 25 responded to this
question. Of those, four (16%) had not been engaged in research in the prior 24 months and were
asked to only complete survey that pertained to the respondents' perception of usefulness of
research technologies, which asked them to assess how useful they feel research technology is to
the healthcare industry and the question that asked how well informed they feel of research
technologies (Questions 8 and 9 on the survey; Appendix C). The results showed that a little
more than half of respondents were principal investigators (52%, n = 1 3), and 32% (n = 8), were
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co-investigators engaged in research at the community hospital. Four (16%) respondents had not
been engaged in research in the prior 24 months. Table 2 shows the sample characteristics of
respondents surveyed.
Table 2
Sample Characteristics
Role in
Research

Principal
Investigator

N*
1 3 (52%)
*N = 25 respondents

CoInvestigator

Not Engaged in
Prior 24 Months

8 (32%)

4 (16%)

Participants were asked how long they had been engaged in research and had the
following choices as answers: 1-5 years, 6-10 years, 11-15 years, 1 6-20 years, or more than 20
years. A total of 22 responses were analyz ed for this question. The largest category of
respondents had been engaged in research for 1-5 years, 40.9% (n = 9). The next category
showed 18.2% (n = 4) of investigators had been engaged in research for 6-10 years, 13.6% (n =
3) had been engaged in research for 1 1 -15 years, 18.2% (n = 4) had been engaged for 16-20
years, and 9.1% (n = 2) of investigators had been engaged in research for 20 or more years.
Figure 2 shows length of participant engagement in research.

14
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Participant Engagement in Research (yrs.)
10
8

z

6
4
2
0
1-5 years

6-10 years

11-15 years

16-20 years

Years of Engagement

•

20+ years

Figure 2. Participant engagement in research (yrs.).

Five categories were numerically coded to determine the mean. Codes were used as
follows: 1-5 years was coded as " 1 ," 6-10 years coded as "2," 11-15 years coded as "3," 16-20
years coded as "4," and 20 and up coded as "5." The mean was 2.36 (SD = 1 .40) which indicates
that on average researchers who responded to the survey have been engaged in research between
6 and 10 years.
Participants were asked which category their most recent research falls under and were
supplied these answer choices: pharmaceutical, medical device, retrospective or observational,
"other," and "all that apply." As shown in Table 3, there were 28 responses to the question
assessing which type of research participants are engaged in. Data showed that 17.9% (n = 5) of
the responses indicated engagement in pharmaceutical research, 1 0.7% ( n = 3) are involved in
medical device research, and 57 .1 % (n = 16) work with retrospective or observational research.
Four respondents chose the "other" option and typed in responses. These responses were not
analyzed for this question because the responses could have been captured by other questions
further along in the survey.
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Table 3
Participant Category ofResearch Engagement I
Category**

Pharmaceutical

Medical Device

Retrospective or
Observational

Other

N*

5 (17.9%)

3 (1 0.7%)

16 (44%)

4
(14.3%)

*N = 28 responses
**Respondents allowed to select "all that apply"

The next question again asked participants to select which category of research they were
currently engaged in and supplied the following choices for answers: investigator initiated,
industry sponsored (clinical trials), and "other," and could select "all that apply." This question
collected 23 responses. Investigator initiated research applied to 78.3% (n = 1 8) of responses,
industry sponsored or clinical trials research applied to 17.4% (n = 4) of responses, 4.4% (n = 1),
respondent was engaged in some other form of research as shown in Table 4. The one respondent
who chose "other" as an answer choice for this question did not supply text to explain their
choice, leaving the field blank.
Table 4
Participant Category ofResearch Engagement 2
Category**
N*

Investigator
Initiated
18 (78.2%)

Industry
Sponsored
(clinical trials)
4 (17.4%)

*N = 23
**Respondents allowed to select "all that apply"

Other
1 (4.3%)
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The participants were asked about how well informed of recent technological
advancements that can be utilized in research they feel they are, to which 25 respondents
supplied data. The selection of answers included: none, little, some, substantial and unsure. Of
the respondents 8% (n = 2) did not feel well informed of recent research technologies at all,
while 24% (n = 6) ofrespondents felt they were informed a little about recent technological
advancements in research. Responses showed that 40% (n = 10) feel somewhat well informed of
advancements, while 28% (n = 7) said they were well informed of the technological
advancements (Figure 3).
Five categories were numerically coded to determine the mean. Codes were used as
follows: none was coded as " l," little coded as "2," some coded as "3," substantial coded as "4,"
and unsure coded as "5." The mean, standard deviation, and variance of the respondents'
selections for this question were reported as (M = 2.88, SD = 0.9 1 , V = 0.83).
Participant Knowledge about Recent Technological
Advancements
12

10
8

N 6

4
2
None

�------,

Little

Some

Substantial

Unsure

Participant Knowledge
Figure 3. Participant knowledge about recent technological advancements.

UTILIZATION OF RESEARCH TECHNOLOGIES

17

The association between how well the participant felt informed of technology
advancements and the amount of time they have been engaged in research was analyzed using
Spearman's rho (n = 22). Using a significance level of 0.0 1 , the correlation coefficient was
0.887, [rs (22) = .887, p < .001 ]. There is a strong positive association between the two variables.
The relationship between the length of time a researcher has been engaged in research and how
well they feel informed of recent technological advancements is also shown in Figure 4.
Association between Engagement in Research and
Participant Knowledge
Well Informed
of..cent
technologlc�
advancements

■ None
■ uni•
■some

0Subst.tnti�I

z

1-5 Years

6-10 Years

11-15 Years 16-20 Years More Than
20 Years

Tlme Engaged In Research as Pl or CO-I

Figure 4. Association between engagement in research and participant knowledge.

The participants were asked if they believed that recent technological advancements are
helpful to research within the healthcare industry, and participants were given these options for
answer selections: none, little, some, substantial, and unsure. This question collected 25
responses. Responses showed that 52% (n = 1 3) of participants believe that technology
advancement are substantially helpful to research within the healthcare industry, while 36% (n =
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9) believe technological advancements are somewhat helpful. Results showed 8% (n = 2) of
respondents believe technological advancements only a little helpful, while one respondent
believes that technology advancements are not helpful to research within the healthcare industry
(Figure 5).

Perceptions on Va lue of Recent Technological
Advancements
15

z

10

None

Little

Some

Substantial

Unsure

Perceptions on Value
Figure 5. Perceptions ·on value of recent technological advancements.

The participants were asked which types of patient-wearable data collection technologies
they use in their current research. Choices included smartwatches (e.g., Apple™ watch), fitness
trackers (e.g., Fitbit™), and biosensor monitors (e.g., patches), and participants were asked to
select "all that apply." A total of22 responses were collected for this question. Responses
showed 13.6% (n = 3) use at least one form of patient wearable data collection technology in
their current research. Fitness trackers are used by 9. I % (n = 2) of all responses in their current
research, and 4.5% (n = I ) use an "other" form of patient-wearable data collection technology,
which was described in text as a mobile phone app. The remaining 86.4% (n = 19) of responses
showed that they do not use a form of patient-wearable data collection in their current research,
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and there were zero responses showing use of smartwatches or biosensor monitors for research
as shown in Table 5.
Table 5
Utilization ofPatient-Wearable Data Collection Technology in Current Research
PatientWearable
Data
Collection
Technology**
N*

Smartwatch

Fitness
tracker

Biosensor
Monitors

None

Other

0 (0%)

2 (9.5%)

0 (0%)

19
(90.5%)

1 (4.8%)

*N=22 responses
** Respondents allowed to select "all that apply"

The relationship between how long a researcher has been engaged in research and which
type of patient-wearable data collection technology they use in their current research was further
explored. Fitness trackers were shown to be used by researchers that have been engaged in
research for 1 -5 years. All the other responses showed they were not using any type of patient
wearable data collection technology in their research regardless of experience levels. This
relationships are shown in Figure 6.
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Patient-Wearable Data Collection Technology
Time Engaged
in Research as
Pl or C0-1

■

1-5 Years
6- 10 Years
• 11-15 Years
D 16-20 Years

■

0 More Than 20 Years

z

Fitness Tracker

None

Wearable Data Collection

Figure 6. Patient-wearable data collection technology.

The participants were asked about which types of smartphone data collection
technologies they use in their current research. The smartphone data collection technologies
category included the following technologies: health/fitness applications, motion tracking sensor
applications (e.g., step tracker), health assessments via smartphone, informed consent via
smartphone, none, an open-ended "other" option for the participant to fill in if it pertained to
their current research, and participants were allowed to select "all that apply." A total of 23
responses were analyzed for this question. Overall 30.4% (n = 7) of responses use at least one
form of smartphone technology in their current research, while 69 .6% (n = 1 6) do not use any
form. A health/fitness app was used by 4.3% (n = 1) respondent for research purposes, 8.7% (n =
2) responses indicated current use of motion tracking sensor applications in current research, and
13.0% (n = 3) of the responses currently utilize a smartphone to conduct health assessments with
research participants. One participant (4.3%) utilizes a smartphone to supply the research subject
with informed consent documents. Table 6 outlines the responses for the smartphone survey
question. Figure 7 shows how long the participant has been engaged in research and what type of
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smartphone technology they are utilizing. This figure shows that the researchers that have been
engaged in research for the least amount of time are utilizing the smartphone technologies more
than the researchers who have been engaged in research for longer lengths of time.
Table 6
Utilization of Smartphone Data Collection Technology in Current Research
Smartphone
Data
Collection
Technology**
N*

Health/
Fitness
App

Motion
Trackin
g App

Health
Assessment
s

Informed
Consent

None

Other

1
(4.3%)
*N = 23 responses

2 (8.7%)

3 (13%)

1 (4.3%)

16
(69.6%)

0
(0%)

** Respondents allowed to select "all that apply"
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Figure 7. Participants' length of engagement and type of smartphone technology being utilized.

The final category asked participants about which type of social media they utilize in
their current research. Options included use of social media to: recruit patients, supply

22

UTILIZATION OF RESEARCH TECHNOLOGIES

information to patients, advertise studies, supply health assessment surveys, use of social media
in other ways and select "all that apply." Responses totaled 22 for this particular question. A total
of 14.3% (n = 3) ofresponses use at least one of these forms of social media to interact with their
study participants. The majority 85.7% (n = 18) do not use social media in their current research.
Supplying research information to participants through social media was used by one respondent
(4.8%), and one respondent uses social media as an avenue to advertise studies. None of the
responses showed they are supplying health assessments to participants via social media, and
only one response (4.8%) showed use of social media in their current research in "other" ways
such as exception from informed consent (EFIC) compliance for emergency research (Table 7).
Table 7
Utilization ofSocial Media Technology in Current Research
Social
Recruitment
Media
via Social
Technology Media
**

Supplying
Information
vis Social
Media

Advertise
Studies via
Social
Media

N*

l (4.8%)

I (4.8%)

0 (0%)

*N = 22 responses

Supply
None
Other
Health
Assessments
via Social
Media
0 (0%)
18
(85.7%) (4.8%)

** Respondents allowed to select all that apply

EFIC compliance refers to informed consent within emergency research. Emergency
research involves human subjects who have a life threatening medical condition that necessitates
urgent intervention and who, because of their condition, cannot provide infonned consent. The
FDA (2013) has developed regulations for this specific type of research, and these can be located
in the Code of Federal Regulations (21 CFR 50.24). The regulations provide additional
protections to these subjects as well.
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The type of social media technology a participant uses was further analyzed against the
length of time the participant has been engaged in research, and this relationship is shown in
Figure 8. The researchers who have been engaged in research between I and 5 years are the
researchers utilizing social media technology to both supply information to their subjects and to
advertise their studies, while the more experienced researchers are not currently utilizing any
form of social media in their research.

Time
Engaged
In
Research
as Pl or
CO-I

• 1-5 Years
• 6- 10 Years
• 11-1s Yea.rs
CJ 16-20 Years
z

Supplying Information
to patients

Advertising studies

None

Social Media and Research

Figure 8. Length of participant engagement and type of social media use.

The final question in the survey allowed participants to share and explain any other type
of technology they utilize in their current research, which was not previously reported in the
survey. This question allowed an open-ended response to which participants could type up to 50
characters. The four responses collected included use of laptops, iPads, web-based data
collection tools, and computers.
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Chapter 4: Discussion

In this survey, community hospital principal investigators and co-investigators of
research were asked 10 questions, eight of which related to research technologies. The survey
assessment was sent to 105 principal investigators and co-investigators that have been engaged
in research within the prior 24 months, of which 29 responded. The objective of this research
was to understand if certain research technologies were being utilized within the research studies
conducted at the community hospital. The technologies examined were categorized as: patient
wearable data collection devices, smartphone data collection technologies, and social media
technologies. The responses showed that only some of the available technologies for research are
being utilized within this community hospital. The participant's data indicated that the
technology being most utilized within research studies at the community hospital are
smartphone-related, followed by patient-wearable data collection technology; social media
technology is the least utilized research technology.
The most utilized category, smartphone technology, included using health fitness
applications and motion tracking sensor apps, providing informed consent to research
participants via smartphones, and providing health assessments of research participants via
smartphones. This category showed that 30.4% of responses indicated utilization of at least one
form of smartphone technology in their current research and that the researchers that are utilizing
this form of technology fall in the 1-5 years of experience category.
The social media category included recruiting through a form of social media, supplying
information to participants through social media, advertising studies to research participants
through social media, and offering health assessments to participants through social media. This
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category of technologies showed that 4.8% of the responses utilize social media technology to
supply information to their research participants. Another 4.8% of responses showed they
utilized social media to advertise their studies, while 4.8% offered EFIC compliance to their
participants via social media technology. Again, the researchers with 1-5 years' experience are
the ones utilizing this form of technology.
The patient-wearable data collection category included the use of smartwatches, fitness
trackers, and biosensor monitors such as patches. Fitness trackers were shown to be utilized by
9.1% of the responses collected, while the majority, 86.4% utilized none of the patient-wearable
data collection technologies. The fitness trackers being utilized at the community hospital are
being used by researchers with 1-5 years' experience.
The survey found that a positive association between the length of time the P.I. or Co-I
was engaged in research and how well informed they were of the various research technologies
available. This relationship was shown in a Spearman's rho correlation with a correlation
coefficient of .887 with a significance level of p < .001. Missing data was not adjusted for in
statistical analysis.
The way the survey was designed could have had the potential to influence participants'
responses to the question that asked how well informed the researcher felt about recent
technological advancements that can be utilized in research (Survey Question 8; Appendix C).
The participants were shown the answer categories that directly pertained to recent research
technologies, such as patient wearable data collection, smartphone and social media (Survey
Questions 5, 6, and 7; Appendix C) before they received the question on how well informed they
felt about these advancements. These could have reminded the researchers of recent
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technological advancements or influenced the answers they supplied to that question that asked
how well the participants felt they were informed of the technologies available.
The significant positive correlation between the length of time a researcher was engaged
in research and how well informed they feel about the available technologies was expected and
seen. The correlation showed that the longer the researcher was engaged in research, the more
informed they felt they were about the available technologies to use in research. This suggests
that the newer a researcher is, the less infonnation they may be receiving about the
advancements in research technology and presents an opportunity for education.
However, the data also show that the researchers who are the newest to research (1-5
years' experience) are the ones who are utilizing the more recent technologies, such as fitness
trackers, smartphone apps, and social media. The researchers engaged in research the longest at
the institution are not utilizing the technologies explored within this study. This may suggest that
the methods being employed by the more experienced researchers are methods they are
comfortable with and are known to work best for them, while the least experienced researchers
are open to exploring the technologies as they begin their research careers. This may also suggest
that the newer researchers are from a younger generation who may be more familiar with these
technologies and probably use them more in their personal lives.
The survey results may not be generalizable to all hospitals and researchers due to the
small sample size (low response rate). The results indicated that the most utilized technology at
this particular community hospital is smartphone technologies, which included the using health
fitness applications and motion tracking sensor apps, providing informed consent to research
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participants via smartphones, and providing health assessments of research participants via
smartphones.
The creation and dissemination of this survey may contribute to the knowledge of which
research technologies are most utilized within an institution. This may help institutions to
manage which studies to participate in, and which to decline based on the knowledge of their Pis
and Co-ls. The survey can also assess how well informed the institution's researchers feel they
are about the available research technologies, which may help the institution to educate
researchers on available technologies. This survey could also be used as an assessment over time
to see if an institution's P.I's and Co-I's utilization of technology changes over time.
Limitations and Future Research
This study design is limited in the manner that it was only administered at one
community hospital and may not be applicable to larger populations. In future studies, the online
survey could be made available to more institutions to yield higher response rates. The type of
hospital may also be a limiting factor, such as general, specialty, government, and university or
academic medical centers. Results could vary from institute to institute depending on the kind of
hospital surveyed. The survey assessment may also have generated a lower response rate due to
it being survey research. Some of the answers to the research question could have been answered
by gaining access to the study protocol records or IRB records, which would indicate which
types of technologies were being used.
Another limitation of this study is that it did not include or mention telemedicine, which
is the use of information technology and telecommunication to provide healthcare from a
distance. Telemedicine is becoming very popular, and it could have been explored and included
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in the assessment tool. Future studies may want to include use of telemedicine in clinical
research within the assessment.
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Chapter 5: Conclusion
The objective of this research was to explore and assess what research technologies were
being utilized at a community hospital. It had a focus on three main categories, including patient
wearable data collection technologies, smartphone technology, and social media technologies,
that can be utilized in clinical research. The results show that few of the technologies explored
through the survey are being utilized in the institution. The most utilized was smartphone data
collection technologies. The survey found a positive correlation between the time a researcher
has been engaged in research as a P.I. or Co-I and how informed they feel recent technological
advancements that can be used in research. A positive association was also found between the
length of time a researcher has been engaged in research and what category of research they are
engaged in, when looking at pharmaceutical, medical device and retrospective or observational
research. The data show that the researchers that have the least amount of experience in years are
the ones that are utilizing the recent research technologies, while the more experienced
researchers are not utilizing the recent technologies. Further research should include a larger
survey sample as well as more than one institution.
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Appendix A: List of Abbreviations
EMU: Eastern Michigan University
P.I.: Principal Investigator
Co-I: Co- Investigator
IRB: Institutional Review Board
FDA: Food and Drug Administration
PHI: Protected Health information
DOA: Delegation of Authority
EDC: Electronic Data Capture
ePRO: Electronic Participants Reported Outcomes
BYOD: Bring Your Own Device
PDA: Personal Digital Assistant
UHSRC: University Human Subjects Review Committee
EFIC: Exception from Informed Consent
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Appendix B: IRB Approval Letters
January 1 8, 2019
Stephanie Otto

Dear Ms. Otto:
Institutional Review Board, expedited review was conducted on
On behalf of the
January 1 8, 201 9 for the following:
Project Entitled: Utilization of Recent Research Technologies within
NHSR-1 9-786 was assigned for IRB tracking purposes.
The JRB determined the project does not meet the definition of human subjects research
and therefore 45 CFR Part 46 does not apply. No further correspondence is required.
The- IRB operates in accordance with Good Clinical Practice Guidelines and applicable
laws and regulations. If there is any aspect of the policies and procedures about which you would
like
further
information
please
v1s1t
the
I IRB website at
ailure to comply with -policy is in violation of federal
drawal of approval and/or funding for your project.

■■■

Sincerely,

IRB Administrator
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Eastern Michigan University Mail - UHSRC-FY 1 8- 1 9- 1 75 - Initial: Initial - Exempt

EASTERN

Page I of 1

Stephani• Otto <sotto1@emlch.edu>

\OCltl<,A' 1 'NIVrlllSITY

UHSRC-FY18-19-175 - Initial: Initial - Exempt
human.■ubJtcts@emlch.edu <human subject•@emich edu>
To )lowan3@emoch edu, sotto1@ellllCh edu

EASTERN

MICHIGAN UNIVERSITY

Wed Jan 23 2019 al 1 1 42 AM

lln iver�ity l l 11m,1n S11bjed!> Review Cornmittet'

Jan 23. 2019 11 42 AM EST
Stephanie Otto
Eastern Michigan Univ•�- School of Health Sciences
Re. Exempt • lntt,al • UHSRC-FY18-19-175 Util,zatlOn of Re•earch Technologies within a local community hosp,tal
Dear Stephanie Otto.

The Eastern Mteh,gan University Human Subjects Review Committee has rendered the deas,on bek)w for Utd1Zab0n of Research Teehnok)gJM wilhin a local

community hospttal You may begin your research
OeciSIOn Exempt

Setected Cateoory Category 2 (t) Research that onty 1ndudes interactions lnvotving educational tests (cognitive, d.agnosbc. apt1lude, achlevemenl), survey
procedures, interview procedures. or observatton of publlc behavor (rncludr.g visual or aud;fory recording)
The info(malJOn obtained is recorded by the inve,t,gator ,n such a manner that the identrty of the human sub,ects cannot readoty be ascertained, duectty or
through tdentlf,ers inl<ed to the subjects

Renewals Exemp1 studies do not need to be renewed VVhen the projed ,s completed, ptease contact human sut>,ec.ts@emich e-du
ModificatJOnS Any plan to atter the study desegn or any stucry document$ must be rev,ewed to determne rf the Exemptdeast00 changes You must submrt a
modrfieat10n request appkcation 1n Cayuse IRS end awart a deciStOn prior to imp�mentaflon
Problems Any deviattons trom the study protocol. unanticipated problems, adverse events. subject comptaints or other problems that may affect the nsk to
human subjects mu•t be reported to the UHSRC Complete an incident report in Cayuse IRS
Follow-up Please contact the UHSRC when your p,o,ect is complete

Please contact human subjects@emtCh edu with any questions or concerns
Sincerely.
Eastern Michigan University Human Subjects Review Committee

https://mail .google.com/mai l/u/O?ik=fc.l0633ed73& view=pt&search=al l&pennmsgid=msg-. .. l /23/20 1 9
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Waiver of Documentation of Consent
,.

,.
,.
,.

,.

·waiver of documentation of consent" means that consent is obtained from the participants, but is done
via verbal consent Q£ by a consent document without the signature lines (commonly referred to as an
'informational sheet'). This option is useful if you are conducting an Internet survey or telephone
research or other types of minimal nsk research.
You will need to document in the research record or other location that a consent process took place.
The consent process should include the required elements of consent If you would like to exclude or
alter the elements, please also complete the Alteration of Consent form
In order to qualify for waiver of documentation of consent for some or all of the participants, the
research study must:
OHRP-regulated research- meet EITHER the 1" or 2nd requirement below [see 45 CFR
46. 1 1 7(c)]
• FDA-regulated research- meet the 2,., requirement below [see 21 CFR 56 109(c)(1)]
Need help?

Waiver of Documentation of Consent

Consent will be obtained, either
verbally or with an Info Sheet

Title of Research Project: Utilization of Recent Research Technology

Which method will you use?
D Verbal consent'-- Please submit a verbal script
181 Consent document without signatures obtained / informational sheet

'Note that the /RB may still require that written information is given to some or all of the
participants (info sheet).

Indicate the documentation that will be used to note that consent took place: The protocol or
departmental procedures should indicate how and where to document the consent discussion (such as in a
progress note, study file or research record).
D Progress note
0 Study file
181 Other
Please indicate the status of the research study:
New Project Application is being submitted - please complete the informed consent
section of the application, describing the consent process that will be used.
D Study has been approved - please attach or describe below the consent process that will
12:1

be used:

Choose either the 1" or the 2"d option, below, for OHRP-regulated research;
Choose the 2nd option only for FDA-regulated research;
Complete both a) and b) for the chosen requirement:

D 1 st Requirement (OHRP only)
Waiver of Documentation of Consent 1 2-2015
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a) The only record linking the participant and the research would be the consent document and
the principal risk would be potential harm resulting from a breach of confidentiality and
privacy. Explain how your study meets this criterion. Please note · the tRB may decide to requ11e that
the researcher provide the parllc1pants with a wr,1te11 statement about the research (rnformat,on sheet/consent
form without signature Imes}

AND

b) Each participant will be asked whether the participant wants documentation linking them
with the research (i.e. sign a consent document or provide evidence that they gave consent
for the study), and the participant's wishes regarding documentation of consent will govern.
D I will comply with this requirement
OR
18) 2

nd

Requirement (OHRP &for FDA)

a) The research presents no more than minimal risk of harm to participants. Explain how your
study meets this criterion. M1nrmal osk means that "the probability and magnrt11de of harm or discomfort
anticipated 10 the research are not greater in and of themselves than those ordinar,ly encountered ,n daily Ille
or dur,ng the performance of routine physical or psychological exam1nat10ns or tests·

This is a minimal-risk study. There are no specific procedures, situations, or materials that
pose serious hazards to patients or personnel. The study is minimal risk because as with all
survey research there Is always a small risk of breach of confidentiality pertaining to the
survey responses. There will be data security measures in place to minimize these risks.
There ls no risk of disclosure of protec1ed health information (PHI). Subject safety will be
ensured through complete lack of the collection of demographic information with the
surveys. There will be no identification through the survey, and surveys will be returned in a
fashion that does not correlate to any email. The survey tool offers anonymous responses by
not recording any personal information and removing all contact association, so the
researcher will not have access to the email addresses of respondents. Qualtrics Is also
known for their recognized standard for proactive risk management, ISO 27001 ensures
information security best practices in asset management, access control, cryptography, and
network security. In addition, I personally will not have Individual emails, and will have the
administrative assistant forward out the emails with the survey link to the P.l.s and Co-l's. I
will only have access to the results of the surveys which are anonymized.Minimal discomfort
at answering the survey questions is another minimal risk although unlikely. Participants
may skip questions that may make them uncomfortable.

AND

b) The research involves no procedures for which written consenl is normally required outside
of the research context. Explain how your study meets this criterion.
The study will only include a survey assessment in which consent is given through
participation. Mention of consent through participation is included in the email in which the
survey link will be embedded as well as the survey itself.

Wa,ver or Documentat10n or Consent 12-2015
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Appendix C: Survey

Research Technology Utilization
Consent Form
Project Title: Utilization of Research Technologies within a local communit hos ital Princi
Investigator: Stephanie Otto, Graduate Student
Purpose: The purpose of this research study is to examine and measure the utilization of
research technologies of the Principal Investigators and Co-Investigators at this institution.
Study Procedures: Participation in this study involves completing an online survey. It should
take between 3 and 5 minutes to complete the survey.
Types of Data Collected: We will ask questions about your involvement in research and what
types of technology your research may utilize. We will not ask for any demographic or personal
information. We will not collect any identifiable data.
Risks: The primary risk of participation in this study is a potential loss of confidentiality. Some
of the survey questions may make you feel uncomfortable. You do not have to answer any
questions that make you uncomfortable or that you do not want to answer.
Benefits: You will not directly benefit from participating in this research. Benefits to society
include understanding utilization of research technology within a community hospital.
Confidentiality: We will keep your responses confidential by using a code to identify your
information. Your responses will be stored in a password-protected computer website. We will
store your responses for three years after the project ends. The principal investigator and the
research team will have access to the responses you provide for research purposes only. We
may share your responses with other researchers outside of this institution and outside of
Eastern Michigan University. If we share your information, we will remove any and all
identifiable information so that you cannot reasonably be identified. De-identified information will
be transferred by email. The results of this research may be published or used for teaching.
Compensation: There is no compensation for completion of this survey.
Contact Information: If you have any questions about the research, you can contact the
Principal Investigator, Stephanie Otto at
researc su iect, you can contact the Eastern Michi
Compliance at
Voluntary participation: Participation in this research study is your choice. You may refuse to
participate at any time, with no penalty or loss of benefits to which you are otherwise entitled.
You may choose to leave the study at any time with no loss of benefits to which you are
otherwise entitled.
Statement of Consent: I have read this form. I click "I consent" below to indicate my consent to
participate in this research study, and will be directed to begin the survey. I click "I do not
consent" below to indicate my choice to not participate in this research study, and will be
directed to exit the survey.
I consent ( 1 )
I do not consent (2)

Page 1 of 6
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Thank you for participating in this survey!
Intentions: This survey has been designed to collect information pertaining to the utilization of
recent research technologies. This information and subsequent analysis will be included as part
of a Clinical Research Administration Master of Science degree thesis. No personal or
otherwise identifying information is required and all responses will be kept anonymous. By
answering the following questions on the survey, you will be providing consent to participate.
Survey Instructions: Please answer all of the questions based on your personal experience.
Certain questions require a single response while others ask that you select all that apply. You
may skip questions that make you feel uncomfortable.

01 I have been engaged in research within the last 24 months as a: Principal Investigator or
Co-Investigator:
� Principal Investigator (Please complete all remaining questions)
Co-Investigator (Please complete all remaining questions)
. I have not been engaged in research in the fast 24 months (please complete only
questions 8 and 9)

02 I have been engaged in research as a P.1. or Co-I for:
1-5 years
6-10 years
1 1 - 1 5 years
• 16-20 years
• 20+ years

Page 2 of 6
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03 My most current research falls under the following category(ies): Select all that apply
Pharmaceutical
Medical device
Retrospective or observational
Other (please specify) _____________________

04 My most current research falls under the following category(ies) :Select all that apply
Investigator initiated
Industry sponsored (Clinical Trials)
Other (please specify)

05 My current research utilizes all of the following patient wearable data collection
technologies: Select all that apply
Smartwatch (e.g. , Applewatch)
Fitness Tracker (e.g. , Fitbit)
Biosensor monitors (e.g. , Patches)
None
Other (please specify)
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Q6 My current research utilizes all of the following smartphone data collection technologies:
Select all that apply
Health/fitness app
Motion tracking sensor app (e.g. step tracker)
Health assessments via smartphone
Informed consent via smartphone
None
Other (please specify)

07 My current research utilizes social media for the following: Select all that apply
Recruitment
Supplying information to patients
Advertising studies
Health assessment surveys
None
Other (please specify)
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08 I feel well informed of recent technological advancements that can be utilized in research.
None
Little
Some
Substantial
Unsure

Q9 I believe that recent technological advancements are helpful to research within the health
care industry.
• None
Little
Some
Substantial
Unsure

Q 1 0 Other than the technologies listed above, please inform us of any other technologies you
utilize in your current research projects, and any other type or research you are engaged in, if
not mentioned above (50 characters or less).
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Appendix D: CITI Certificates

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI l'ROGRAM)
( O\lfl.t::TIO' 1<n010 . f.\l<l I 01 ?
( (It R>I \\ORI, RE()I IRE\ll. , 1 ,•
• NOTE Scores on !his AMW'Crot013 Rroon reflect quiz. c�l•om al the hme al reqwements lor the co1.K1e were mel See hs1 below '°' detaHs.
SH: sepa,a1e TraMCllPt Repon tor mo,e recent QUI.I $C0te1 "1dudll'IQ lhOst on optlOnal (supplemental) cou·ae dements
•
•
•
•
•

NenM:
Institution Aff11lalion:
lnatltut.Ori Emtll,
Institution Unit
Phorw.:

Stephanie Otto (10 533009,)
Eastem Mlehigan University (10 1781)
sollo1Ctmlch edu
Sod
73-42771978

•
•
•
•

CuNk:ulum Group:
Cou,... Ularner Group:
Stage:
DHc:rtpllon·

Socal & BehalflOrlf Sciences Responaibte: Conduct of Researcn
Same at C11ncutum Group
SI1ge 1 • RCR
This C:Ol#le 1s fof lnvealigatOfs, Maff encl tludents with an an1eres1 or focus N'\ Soc&.J and Behavk>ral resea,ch
nus cours.e containl leld embedded use studJes ANO qtNZe.s

• R.cordlO:
• Completion Oat•:
• Eapk'atktn 0.te:
• Mlnknum Pualncr
• Report9d Score•:

18484006
25-Jan-2016
NIA
80
89

REQUIRED AND ELECTIVE MODULES ONLY
Responsible CondUd o1 Refelfc:h (RCR) Cown tnt.toduc:tton (ID 1522)
Resn,m M<seonduc1 (RCR-8a51c) (ID 16604)
Olla MIMl)Ome,_ (RCR·lloslc) (10 16600)
Aulhor1hip (RCA-Bade) (10 16597)
Peer Review (RCR·Bollc) (10 16603)
Memorlng (RCR-8as,c:) (10 16602)
Using AnmM Subfecb in RKearCh (RCR•BH�) 00 13:)()1)
Conti.CU ol lnlerell (RCR-8aslc) (10 165119)
ColaboraWt Researeh (RCR..S..sk:) (ID 16598)
Resea,cn lttvOfviog t-tum.n Subjects (RCR•BIMC) (ID 13566)
Respons� Coodud of Research (RCR) Course Condusion (ID 10.C3)

DA
TE COMPLETED
25-Jan-2016
25--Jao.2016
2S-Jon-2016
l'>Jan-2016
2$-Jan-2016
25-Jan-2016
2S-Jan-2016
25-Jan-2016
25--Jan-2016
25-Jan-2016
25-Jan-2016

SCORE
NoOw
515 (100%)
5/5 (100%)
415 (80%)
415 (80%)
515 (100%)
415 (80%)
4/5(80%)

415 (80%)
515 (100%)
NoOu,z

For this Report to e,. v•lkl, tM ••m•r ktentffled above mu-st halve had • valkt afftll.atlon with tha CITI Pn>9ram subscrfbfng ln.stltwlk>n
kffntJt'lt(f a.bo,,. or Mva been • paid '"dependent LHmer.
Varity 11 w.ywGrl1Qf99{000 Ot9fYCDtxl?kfat509bH351➔t6a·1f0§:683bd50bJb31·10181006
CoH.bofatfva lnstitutlonal Training lnltlallve (Cm P,09ram)
E.ma.1 $VPP9r1:1>ci!'SX99!tffl AlA
Phone 888-529-5929
Web htlP1(Jwww PJICXPPCfffl9!9
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COI.LABOHATIVF. INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
( 0\11'1 HIO� Rtr!llrr - r.,R I I or l
( Ill RSf II ORI,; Rf'QI IRF\IISI S•
• NOTE Scores on this Reawremcn1& Rcoon refleci qu,z complet,ons at the 11me all requirements ror 1he course were mel See 11s1 below f0< details
See separate Transcnpl Repor1 f0< m0<e rec.en! qu,z ,co,es. 1ndud1ng lho&e on ophonal fSupplemenlal) covrs.e elements
• Name:

• Email:

S1ephan;e Ono (ID 5759297)

, Institution Affiliation:

• Institution Unit:

• Phone:

a,,..,.,

• Currtculum G,oup:
Good
Practi<e c...,.. (GCPI
• Course Lumer Group: Same as Cumculum Group
• Stage:
Stage 1 - GCP
• Description:
This ICH E6 GCP Investigator She Training meel5 the Minimum Criteria for ICH GCP Investigator Site
Pt-rsonnel Training identJfled by TranaCelerate BloPharrna as necessary to enable mutual rec:ognlUon of
GCP training among trial apon1ora.
•
•
•
•
•

ReportlO:
Completion Date:
Expiration Date:
Minimum P111fng:
Reported Score':

20672663
31-Aug-2016
30-Aug-2020
85
96

REQUIRED ANO ELECTIVE MODULES ONLV
The CITI GoOd Clm,cal Practice Course for Clinical Trials Involving Drugs and OeV1ces (10 1350)
Ovetv1ew of New Drug Development (ID 1351)
Overview of ICH GCP (ID 1 352)
ICH - Companson Between ICH GCP E6 and U.S FDA RegulatJons (10 1354)
Conduaing lnvest,gator-lmllated Stuches According 10 FDA Regulahons and GCP (ID 1355)
Investigator Obhgat,ons in FOA-Regula1ed Researeh (10 1356)
Managrrig lnvesIigat1onal AgenIs AcCOJding 10 GCP Requiremen1s (10 1357)
Overvtew of U.S FDA Regulations for Medical Devices (10 1358)
Informed Consenl 1n Omteal Tnals of Drugs, 81olog1c.s and Devices (ID 1359)
Detecting and Evalual.lng Advel'$e Evenls (ID 1360)
Reporung Senous Adverse Events (ID 1361)
Audits and lnspecuons of Chrltcal Tnals (ID 1 363)
Monitonng of Chn1cal Trials by Industry Sponsors (ID 1362)
Completing the CITI GCP Course (ID 1364)

DATE COMPLETED
31-Aug-2016
31-Aug-2016
31-Aug-2016
31•Aug-2016
31-Aug-2016
31-Aug-2016
31•Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2015

SCORE
No Quiz
313 (100%)
515 (100%)
31• (75%)
3/4 (75%)
3/3 (100%)
515 (100'41
515 (100%)
3/3 (100'4)
.,. (1 00%)
.,. (100%)
.,. (100%)
515 (100%)
515 (100'4(
No Quiz

For this Report to be valid, lhe learner idtnlified above must han had a valid affiliation with th• CITI Program 1,ub1c:.riblng lnstltullon
Identified above or have been • paid Independent Leamer.
Verify at WWttg\1 pcogram PCatwnty!?kQ1f◄Scfib-8§72◄eh9·A0nS·ba§6b7279e6f·20672663

CITI Program

Email 5µppQO@g\tp[OQtaOO prg
Phone 888-529-5929
Web hUQS /{www.t;Jt1progrem prg
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COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
1"0\11'1 I TIO� Rl"rORl • P.\R"I 2 m l
f 01 RSI \\ ORli 1 R "SCRlrT••
" NOTE SC.Ores on this Transmol Bcooa rellea Che mos1 current QUtZ completions. 1ndud,ng qr.1ues on optional (�upptemental) dements of the
course See t.sl bek>w fo, oelalts See s.eparate Requirements Report lor the ,epone<I acores 11 lhe time aN requ1tement1 fot' the course were mel
SleJ)Nn,e Otto (10 5759297)
• ln1tttu1ion Afflh1tion:
• ln1Ututlon Unit.
• Phone:
•
•
•
•

Curriculum Group:
Good ().oicaJ Practice Course (GCP)
Court• Ltam•, Group: SI.me as Cumcutum Group
Stage.
Stage 1 . GCP
This ICH U GCP lnveatlgator Site Training meetc the Minimum Ct1t1ri1 for ICH GCP Investigator She
Oetenptton:
Peraonnel Training ldentrfied by r,.n,Celerate BloPherm,i H ntc:HH,Y to enable mutual Nc09nttlon of
GCP t,alnlng among trlal aponlot'l.

• Report 10:
• Report Date:
• Cu""nt Score··:

20672663
13-Jan-2017
96

REQUIRED, ELECTIVE, ANO SUPPLEIIENTAI. IIQOULES
The CITI Good CMlcaJ Praa,ce Courn for a.n,eal Trials lnvol\l'lng Drugs and DelfloeS (10 13SO)

Ovtf\llew of New Drug Development (ID 1351)
OveMOW of ICH GCP (ID 1352)
ICH - Companson Between ICH GCP E6 and U S FDA Regl.Aabon& (ID 1354)
Conduct,og lnveltlgttor-lnmated Studies Accon:hng to FOA Regulal1ons and GCP (ID 1355)
kWesbgllOl Obhgations in FDA-Regulated Rese,rch (10 135&)
Managing lnYest,gat1onal Agents Acc:o,ding 10 GCP Aeq\Jllemen1s 00 1357)
O�wof U S FOA Reguta1,ons tor Medic.al Devices (10 1358J
Informed Consen1 1n Otn1c,I Ttials of Drugs, BiologtCS and Device$ (10 1359)
Detect,ng and Evaluating Adverse Events (10 1360}
Reporting Serious Adverse EWNs (10 1361}
Audits Ind Inspections ofO1n1cal Tn,1$ tl0 1363)
M001tor10g ofChnal Tnals by Industry Sponsors (10 1382)
Complel,ng lhe ClTI GCP C..... (10 136,)
Saint Jo� Metcy Huflh Sysrem (ID 1271 1 1

MOST RECENT
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aog-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31-Aug-2016
31•Aug·2016
31-Aug-2016

SCORE
3/3 (100%)
515 (100%)
3/◄ (75%)
3/◄ (75%)
3/3 (100%)
515 (100%)
515 (100%)
3/3 (100%)
.,. (100%)
"'" (100%}
<4/4 (100%)
515 (100%)
515 (100%)
No au,,
NoOUtz

For this Report to be valid, th• teamer Identified above must hav. had • valid affllbitlon wfth the CITI Program tubscrfblng lnatituUon
id•ntlfi•d above or have bNn I paid lnd•pendent LHm•r.
V•rtty II WWWRi'OfPA!lm grgfyl!ptynkq◄f4St.6b·8672::iob9•8oa$-bi66bZ?79ft6f-20672663
Collabonnlve lnathutional Training Initiative (CITI Program)
Email SUPP90CPPlmrggram prg
Phone 888-529-5929
Web hnPS1/wwwP11Df00'1Wgrg

Xu Zhang
404-661-2526, xzhang.ga@gmail.com
8181 Fannin St, #328, Houston, TX, 77054
SUMMARY OF QUALIFICATIONS
• Extensive experiences in trial design and trial proposal/protocol development
• Expertise in causal inference, propensity score, model validation and calibration, cost-effective
analysis, variable selection, multi-state model, diagnostic test evaluation, analysis of time-to-event data
and longitudinal data
• Profound knowledge in statistica l/big data/machine learning methodologies
• Proficiency in SAS, R and STATA
WORK EXPERIENCES
Associate Professor, 2016 - present
University of Texas Health Science Center at Houston, Houston, TX
• Perform univariate, stratified and multivariable analyses of various types of data; implement variable
selection using the forward stepwise and LASSO methods; validate and calibrate models.
• Conduct size/power calculations and write statistical analysis plans for proposals of clinica l trials,
observational studies and experiments.
• Performed univariate and multivariable analyses of survival endpoints including single, composite
surrogate and dynamic endpoints; defined the novel dynamic endpoint for post-transplantation
outcome in leukemia patients by creating the multi-state model.
• Taught Categorical Data Analysis to a class of 40+ students; delivered the lecture about Bayesian
Network.
Associate Professor, 2013 - 2016
Department of Data Science, University of Mississippi Medical Center, Jackson, MS
• Developed statistical components of single-arm and randomized two- or multi-arm phase II clinical
trials with binomial, time-to-event and continuous endpoints; determined sample size and power based
on multiple endpoints; wrote statistical analysis plans for the primary and secondary endpoints.
• Implemented group sequential methods using the error spending function in trial design; estimated
probabilities of stopping at stages and the expected number of enrollment; implemented the sequential
probability ratio test (SPRT) to define the safety stopping rule.
• Served as member of Institutional Review Board; reviewed and critiqued clinical trial proposals and
protocols; clarified the statistical concepts in protocols to the board.
• Collaborated with radiologists to evaluate accuracy and reproducibility of continuous markers as well
as dichotomous and ordinal diagnostic tools.
• Conducted cost-effective analysis (CEA) to compare surgery versus surveillance strategy for patients
with Bosniak Ill renal cyst; created the multi-state models for estimating gender-specific lifetime;
calculated quality-adjusted lifetime and cost based on Medicare reimbursement rates; evaluated and
interpreted the incremental cost-effectiveness ratio (ICER).

• Explored genomic data such as Gene Expression Omnibus (GEO}, the Cancer Genome Atlas (TCGA} and
EMBL-EBI to screen for or validate genes predictive of cancer genesis/progression; programmed with
R/Bioconductor to correlate multiple genes or associate genomic markers with survival outcomes.
Assistant Professor, 2005 - 2012
Department of Mathematics and Statistics, Georgia State University, Atlanta, GA
• Conducted methodological researches on competing risks, adjusted survival, adjusted cumulative
incidence and length-biased sampling.
• Collaborated with researchers in nutrition to analyze national survey data (NHANES) to examine tend
of vitamin D in US population.
• Directed student to perform principal component analysis (PCA) on dietary intake data and associate
dietary factors to vitamin D deficiency; collaborate with biologists to cluster marine animals using the
multidimensional scaling (MDS) method.
• Taught at both undergraduate and graduate levels including Elementary Statistics, Biostatistics, SAS
Programming, Multiple Regression, and Longitudinal Data Analysis; wrote comprehensive and qualifying
exams; contributed to the curriculum development; directed five students to write theses and
dissertation.
Statistician, 2003 - 2005
Department of Mathematics and Statistics, Georgia State University, Atlanta, GA
• Served as key statistician on projects studying effects of hospital and surgeon volumes on survival
using the Medicare-SEER linked database; implemented propensity score to control for the imbalanced
distribution of characteristics in arms; employed the frailty model to adjust for correlation of clustered
data.
• Analyzed the Medicare claim database (5% random sample) to study healthcare disparity.
EDUCATION
PhD in Biostatistics, 2005, Medical College of Wisconsin, Milwaukee, WI
MS in Applied Statistics, 2001, Northern Illinois University, DeKalb, IL
BS in Economics, 1995, Northern Jiaotong University, Beijing, China
PUBLICATIONS
Selected from a total of 76 peer reviewed publications:
(Citations as first/corresponding author 300+; Citations as second author 800+; Total citations 2400+)
1. Zhang X, Loberizab FR, Klein JP, Zhang MJ (2007). A SAS macro for estimation of direct adjusted
survival curves based on a stratified Cox regression model. Computer Methods and Programs in
Biomedicine 88, 95-101. [Citation: 170; referenced by SAS/STAT manual]
2. Zhang X, Zhang MJ (2011). SAS macros for estimation of direct adjusted cumulative incidence
curves under proportional subdistribution hazards models. Computer Methods and Programs in
Biomedicine 101, 87-93. [Citation: 63)

3. Zhang X, Zhang MJ, Fine JP (2011). A proportional hazards regression model for the
subdistribution with right censored and left truncated competing risks data. Statistics in
Medicine 30, 1933-1951. [Citation: 44)
4. Zhang X, Akcin H, Lim HJ (2011). Regression analysis of competing risks data via semi-parametric
additive hazards model. Statistical Methods and Applications 20, 357-381.
5. Zhang X (2012). Nonparametric inference for inverse probability weighted estimators with a
randomly truncated sample. Journal of Data Science 10, 673-691.
6. Zhang X (2013). Comparison of restricted mean survival times between treatments based on a
stratified Cox model. Bio-Algorithms and Med-Systems 9(4), 183-189.
7. Zhang X (2015). Nonparametric inference for an inverse-probability-weighted estimator with
doubly truncated data. Communications in Statistics - Simulation and Computation 44, 489-504.
8. Zhang X, Li J and Liu Y {2017). Inference for probability of selection with dependently truncated
data using a Cox model. Communications in Statistics - Simulation and Computation 46:1944-57.
9. Qi L, Zhang X, Wang L, Sun Y, Zhao Y (2018). Weighted estimators for additive hazards models
with missing covariates. Annals of the Institute of Statistical Mathematics,
https://doi.org/10.1007/s10463-018-0648-y
10. Liu Y, Li J, Zhang X* {2017). Analysis of dependently truncated data in Cox framework.
Communications in Statistics-Simulations and Computation 47:1677-95.
11. Zhang X, Jiang Y, Zhao Y, Akcin H (2018). Nonparametric estimation of a cumulative hazard
function with right truncated data. In Frontiers of Biostatistics and Bioinformatics. Springer.
Complete list of publications can be found at
https://scholar.google.com/citations?user=sVwptR4AAAAJ&hl=en
AWARDS AND PROFESSIONAL MEMBERSHIPS
• Director's Award, Division of Statistics, Northern Illinois University, 2001
• Student of the Year, Division of Biostatistics, Medical College of Wisconsin, 2003
• American Statistical Association, 2001 - Present
• International Chinese Statistical Association, 2008 - Present
• Invited session organizer at ENAR 2015 and ICSA 2016
• Referee for Journal of the American Statistical Association, Biometrics, Statistics in Medicine, Lifetime
Data Analysis, Journal of Biopharmaceutical Statistics and etc.
• Guest editor of New Advances in Biostatistics, special issue of Journal of Probability and Statistics,
2017-2018
TECHNICAL SKILLS
• Software: SAS, R, STATA, R/Bioconductor, GraphPad
• Programming Languages: R, MySQL, Python

